ATO-101 (211At-labeled girentuximab) / ATONCO, Telix - LARVOL DELTA

Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Institut Cancerologie de l'Ouest | Trial completion date: Aug 2028 ➔ Jan 2030 | Initiation date: Feb 2026 ➔ Jan 2027 | Trial primary completion date: Aug 2027 ➔ Jan 2029

First-in-human • Trial completion date • Trial initiation date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU) (clinicaltrialsregister.eu) - P1 | N=24 | Not yet recruiting | Sponsor: Institut De Cancerologie De L Ouest

First-in-human • New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Institut Cancerologie de l'Ouest

First-in-human • New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor